Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlodipine/Losartan and Rosuvastatin drug interaction study
NCT02140489Phase 1Unknown
- Sponsor
- Hanmi Pharmaceutical
- Start
- Feb 2014
- Primary completion
- May 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Amosartan and rosuvastatin in hypertension (HTN) and hypercholesterolemia (3 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Curve from time 0 to last measurable concentration at 72 hours. Status: unknown.
02
Drugs
Amosartanrosuvastatin
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT02140489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140489.